Presentation is loading. Please wait.

Presentation is loading. Please wait.

Hepatitis web study Hepatitis web study Sofosbuvir in Genotype 2 or 3 FUSION Trial Phase 3 *Note: Published in NEJM in tandem with POSITRON Trial (GT 2,3.

Similar presentations


Presentation on theme: "Hepatitis web study Hepatitis web study Sofosbuvir in Genotype 2 or 3 FUSION Trial Phase 3 *Note: Published in NEJM in tandem with POSITRON Trial (GT 2,3."— Presentation transcript:

1 Hepatitis web study Hepatitis web study Sofosbuvir in Genotype 2 or 3 FUSION Trial Phase 3 *Note: Published in NEJM in tandem with POSITRON Trial (GT 2,3 Unable to receive PEG) Treatment Experienced Jacobson I, et al. N Engl J Med. 2013;368:

2 Hepatitis web study Source: Jacobson I, et al. N Engl J Med. 2013;368: Sofosbuvir + RBV in Treatment-Experienced HCV GT 2 or 3 FUSION Trial: Features

3 Hepatitis web study Source: Jacobson I, et al. N Engl J Med. 2013;368: N =98 Sofosbuvir + RBV 16 weeks Sofosbuvir + RBV 16 weeks Sofosbuvir + RBV 12 weeks Sofosbuvir + RBV 12 weeks N =103 Sofosbuvir + RBV in Treatment-Experienced HCV GT 2 or 3 FUSION Trial: Design Placebo Drug Dosing Sofosbuvir: 400 mg once daily Weight-Based Ribavirin (in 2 divided doses): 1000 mg/day if < 75 kg or 1200 mg/day if ≥ 75 kg 024 Week SVR12

4 Hepatitis web study Sofosbuvir + RBV in Treatment-Experienced HCV GT 2 or 3 FUSION Trial: Results FUSION: HCV RNA <25 IU/ml by Study Timepoint Source: Jacobson I, et al. N Engl J Med. 2013;368: SOF= Sofosbuvir; RBV = Ribavirin 97/10093/95100/10095/9550/10069/95

5 Hepatitis web study Sofosbuvir + RBV in Treatment-Experienced HCV GT 2 or 3 FUSION Trial: Results FUSION: SVR12 by Genotype and Treatment Duration Source: Jacobson I, et al. N Engl J Med. 2013;368: SOF = Sofosbuvir; RBV = Ribavirin 31/3630/3219/6439/63

6 Hepatitis web study Sofosbuvir + RBV in Treatment-Experienced HCV GT 2 or 3 FUSION Trial: Results FUSION: SVR12 by Liver Disease Source: Jacobson I, et al. N Engl J Med. 2013;368: SOF = Sofosbuvir; RBV = Ribavirin 39/6448/6311/3621/32

7 Hepatitis web study Sofosbuvir + RBV in Treatment-Experienced HCV GT 2 or 3 FUSION Trial: Results FUSION: SVR12 by Genotype, Cirrhosis, and Duration of Therapy Source: Jacobson I, et al. N Engl J Med. 2013;368: SOF = Sofosbuvir; RBV = Ribavirin Genotype 2 Genotype 3 25/2623/236/107/914/3825/405/2614/23

8 Hepatitis web study Source: Jacobson I, et al. N Engl J Med. 2013;368: Sofosbuvir + RBV in Treatment-Experienced HCV GT 2 or 3 FUSION Trial: Conclusions Conclusions: “Our findings suggest that 12 weeks of treatment with sofosbuvir and ribavirin can be an effective option for patients with HCV genotype 2 infection. However, for patients with genotype 3 infection, particularly those who have cirrhosis or who have not had a response to prior treatment with interferon, extending the duration of treatment to 16 weeks may provide an additional benefit.” *Note: This conclusion pertains to both the FUSION and POSITRON trials, which were published in tandem

9 Hepatitis web study Hepatitis web study This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Online Hepatitis Web Study Funded by a grant from the Centers for Disease Control and Prevention. This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Online Hepatitis Web Study Funded by a grant from the Centers for Disease Control and Prevention.


Download ppt "Hepatitis web study Hepatitis web study Sofosbuvir in Genotype 2 or 3 FUSION Trial Phase 3 *Note: Published in NEJM in tandem with POSITRON Trial (GT 2,3."

Similar presentations


Ads by Google